EGFR-targeted Therapy for Gastric Cancer

• Status: Recruiting
• Trial end date: 2023-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Based on targeted NGS panel results, metastatic gastric cancer patients with gene amplifications will receive either anti-EGFR antibody (GC-1118) in combination with weekly paclitaxel as a second-line therapy.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Cancer Center, Korea
• Collaborator: Korean Cancer Study Group
• Treatments: Albumin-Bound Paclitaxel; Antibodies; Immunoglobulins; Paclitaxel

Criteria

Key inclusion criteria

1. Histologically-proven gastric and gastroesophageal junction adenocarcinoma

2. Refractory to first-line chemotherapy for metastatic disease

3. Presence of at least 1 measurable lesion according to RECIST version 1.1

4. EGFR gene amplification or strong (3+ or 2+) EGFR immunostaining

Key exclusion criteria

1.Prior exposure to taxane or EGFR-targeted therapy